You are here

Nightstar Therapeutics to Participate in Multiple Conferences in November

WALTHAM, Mass. and LONDON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in the following investor conferences in November.

  • Jefferies London Healthcare Conference on Wednesday, November 14, 2018 at 12:40 p.m. GMT in London
  • Barclays Gene Editing & Gene Therapy Summit on Thursday, November 29, 2018 at 8:30 a.m. ET in New York City

The presentation at the Jefferies London Healthcare Conference will be webcast. To access the live webcast, please visit A replay of the webcast will be available on the Nightstar website for two weeks following the conference.

About Nightstar
Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar’s lead product candidate, NSR-REP1, is currently in Phase 3 development for the treatment of patients with choroideremia, a rare, degenerative, genetic retinal disorder that has no current treatments. Results from a Phase 1/2 trial of NSR-REP1 were published in Nature Medicine in 2018, in The New England Journal of Medicine in 2016, and in The Lancet in 2014. Nightstar’s second product candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease. In September 2018, Nightstar announced preliminary safety and efficacy data from the XIRIUS trial for the first five cohorts (combined n=15) of the dose escalation study at the EURETINA medical meeting.

For more information about Nightstar or its clinical trials, please visit

Senthil Sundaram, Chief Financial Officer
Brian Luque, Sr. Manager, Investor Relations

Thursday, November 8, 2018 - 06:05